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Endometrial carcinoma in vitro chemosensitivity testing 
of single and combination chemotherapy regimens using 
the novel microculture kinetic apoptosis assay:  
implications for endometrial cancer treatment
Karen S. Ballard1, Howard D. Homesley1, Charles Hodson1, Cary A. Presant2, 
James Rutledge3, Allan Hallquist2, Mathieu Perree2
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Objective: The in vitro microculture kinetic (MiCK) apoptosis assay has been used to predict single or combination 
chemotherapy response in leukemia patients.  This feasibility study addressed MiCK in endometrial cancer specimens.
Methods: Endometrial cancer specimens from total abdominal hysterectomies were processed at a central laboratory.  
Single cell suspensions of viable endometrial cancer cells were plated in individual wells. Single and combination 
regimens were tested: combinations of doxorubicin, cisplatin, and paclitaxel and carboplatin and paclitaxel (Gynecologic 
Oncology Group [GOG] 209 endometrial cancer phase III trial arms) as well as single agent testing with paclitaxel, 
carboplatin, doxorubicin, cisplatin, ifosfamide, and vincristine (active agents in GOG trials). Apoptosis was measured 
continuously over 48 hours. 
Results: Fifteen of nineteen patients had successful assays. The highest mean chemo sensitivity was noted in the 
combination of cisplatin, doxorubicin, and paclitaxel with lower mean chemosensitivity for carboplatin and paclitaxel.  
Combination chemotherapy had higher chemosensitivity than single drug chemotherapy. However, in 25% of patients 
a single drug had higher chemosensitivity than combination chemotherapy. As single agents, ifosfamide, cisplatin, and 
paclitaxel had the highest kinetic unit values.
Conclusion: Using a panel of agents simulating clinical dose regimens, the MiCK assay was feasible in evaluating in 
vitro chemosensitivity of endometrial cancer. MiCK assay results correlated with GOG clinical trial results.  However, 
25% of patients might be best treated with single agent chemotherapy selected by MiCK. Ifosfamide, cisplatin, and 
paclitaxel appear to have high activity as single agents. MiCK may be useful in future new drug testing and 
individualizing endometrial cancer patient’s chemotherapy management.
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INTRODUCTION
Apoptosis is a cell’s innate ability to undergo programmed 
death due to detrimental or incompatible derangements in its 
DNA. Many drugs can also trigger a cell to undergo apoptosis, 
and this is the basis for most chemotherapy treatment of 
cancer. There exist assays to test resistance of tumor cells to 
chemotherapy by measuring the amount of living cells re-
maining after exposure to higher than clinical doses. The 
more recently developed, automated microculture kinetic 
(MiCK) assay measures sensitivity of tumor cells to chemo-
therapy using clinical doses of drug by measuring the fraction 
of cells that have undergone apoptosis.1-4
The MiCK assay has been previously tested on cells from pa-
tients with acute myeloid leukemia and has been used to di-
rect chemotherapy choice in leukemia patients.5 Studies com-
paring clinical criteria to the MiCK assay showed the assay 
was better able to predict complete remission and survival in 
acute myeloid leukemia patients.6,7 Chemotherapy induced 
apoptosis has also been studied using MiCK assay in solid tu-
mors such as neuroblastoma and colon adenocarcinoma.8,9
With this knowledge, we explored the possibility that the 
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MiCK assay may be used to create patient specific drug sensi-
tivity profiles with endometrial cancer. An in vitro chemo-
sensitivity test to determine cancer susceptibility to various 
chemotherapeutic drugs might aid physicians in choosing the 
most effective agent(s) and their most effective concentra-
tion. The MiCK assay might be used with endometrial cancer 
cells to calculate the most lethal chemotherapy to these cells. 
This data could allow physicians to choose the best agent(s) 
saving time, toxicity, and the expense of administering a less 
active regimen. The feasibility of MiCK in endometrial cancer 
was addressed in this prospective trial. The hypothesis was 
that a preliminary prospective trial of a small number of speci-
mens would indicate the possible success of this methodology 
to mimic Gynecologic Oncology Group (GOG) clinical trial 
findings in endometrial carcinoma.
MATERIALS AND METHODS
The collection of the tissue specimens was performed en-
tirely under sterile technique. The surgeon and pathologist 
opened the uterus in the operating room and collected the sol-
id tumor. At least 1.5 cm3 of viable tumor tissue was collected 
trying to avoid fat or necrotic tissue. If the tumor specimen ex-
ceeded 2 cm3, it was then cut into smaller pieces. The speci-
men was placed into a tube containing sterile DiaTech trans-
port media. The tube was labeled with institution name, pa-
tient name, date and time of collection, and anatomical site. 
The tube was sealed inside a biohazard bag and placed inside 
a Styrofoam box with three ice packs for transportation. The 
package and patient information forms were sent overnight 
via Federal Express approximately 1,472 km from Greenville, 
North Carolina to the DiaTech Oncology laboratory in Mon-
treal, Quebec, Canada.
1. Tumor cell purification
Tumor excisions or biopsies were processed within 24 to 48 
hours of collection. The specimen was minced with scalpels 
and tissue pieces were digested with 0.25% trypsin and 0.08% 
DNase for one to two hours at 37oC. Non-digested tissue was 
removed by filtration through a 100-micrometer cell strainer. 
When necessary, non-viable cells were removed by density 
gradient centrifugation. The resulting viable cell suspension 
was then incubated for 30 minutes at 37oC in a tissue culture 
flask to remove macrophages by adherence. Non-adherent 
cells were collected and the remaining hematopoietic cells 
were depleted after 30 minutes incubation with specific anti-
body-coated magnetic beads. The final cell suspension was 
plated into a 96 well half-area plate, 120 microliter aliquot per 
well. The plate was incubated overnight at 37oC with 5% car-
bon dioxide humidified atmosphere. The cell seeding concen-
tration varied between 5×104 to 1.5×105 cells per well. It was 
adjusted depending on cell volume to give adequate well co-
verage. 
The purity of the cell preparation was analyzed by im-
munohistochemistry and Wright-Giemsa staining to confirm 
malignant cell content and phenotype. A pathologist eval-
uated each specimen to be certain all tumors were endo-
metrial carcinoma. To be deemed acceptable for the MiCK as-
say, the final cell suspension should contain at least 80% of tu-
mor cells. Based on our experience, 20% or less nonmalignant 
cells in the suspension is not enough to interfere with the 
results.3
Human JURL-MK2 chronic leukemia blast crisis cell line 
(DSMZ, Braunschweig, Germany) was used as a positive con-
trol for MiCK assays done with patient tumor cells. RPMI- 
1640 medium without phenol red was used for all cultures. It 
was supplemented with 10% fetal bovine serum, 100 units/ 
mL penicillin, and 100 micrograms/mL streptomycin. Cell 
counts and viability were evaluated by trypan blue exclusion 
dye with a hemocytometer.
2. MiCK assay for apoptosis
The MiCK assay procedure was adapted from the method de-
scribed previously.1,3,6 The purified tumor cells were in-
cubated overnight at 37oC in a 5% carbon dioxide humidified 
atmosphere incubator to allow the cells to adapt to the culture 
environment and attachment to the culture plate. Cell growth 
is not necessary for the MiCK assay. After this incubation, the 
chemotherapy drugs were added in the wells of the 96 well 
plate in 5 microliter aliquots at various concentrations. Single 
and combination regimens were tested; including the combi-
nation of doxorubicin+cisplatin+paclitaxel and the combina-
tion of carboplatin+paclitaxel (arms for the current GOG en-
dometrial cancer phase III trial GOG 209) as well as single 
agent testing with paclitaxel, carboplatin, doxorubicin, ifosfa-
mide (4-hydroperoxyifosfamide was used as a surrogate ac-
tive metabolite) and vincristine (all active agents in GOG tri-
als). Following drug addition, the plate was incubated for 30 
min at 37oC in a 5% carbon dioxide humidified atmosphere 
incubator. Each well was then overlaid with mineral oil, and 
the plate was placed into the incubator chamber of a micro-
plate reader (BioTek instruments, Winooski, VT, USA). The 
optical density at 600 nanometers was monitored every 5 mi-
nutes over a period of 48 hours. The cells remained in contact 
with the drugs for the entire 48 hours of the test.
3. Data processing and statistical analysis
All data acquisitions and calculations during the MiCK assay 
were done with DiaTech Oncology proprietary software 
ProApo. To provide a kinetic representation of the drug re-
sponses, the optical density (OD) readings were plotted 
against time. Apoptosis is characterized by a steep increase in 
OD while necrosis shows a decline in OD values.2 The MiCK 
assay can therefore distinguish apoptotic versus necrotic cell 
death. For convenience, the measure of apoptosis is reported 
in kinetic units (KU) as described in detail previously.3 Briefly, 
the maximum slope of the apoptotic curve (Vmax) is calculated 
for each plot of drug treated microculture. It is then compared 
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Table 1. Patient characteristics
Characteristics Values
Age, yr
   Mean
   Median
   Range
Viable cells
Stage
   IA
   IB
   IC
   IIA
   IIIA
   IIIC
Grade*
   1
   2
   3
Histologic type
   Endometrioid
   Papillary serous
   Clear cell
   Carcinosarcoma
69.1
69
46-91
15/19 (78.9%)
2
5
6
1
4
1
4
4
11
11
3
2
3
*Clear cell and papillary serous carcinomas were classified as grade 3.
Table 2. Common clinical chemotherapy doses for endometrial car-
cinoma as simulated in the microculture kinetic assay
Regimens tested Drug Simulated clinical dose
1 Cisplatin
Doxorubicin
Paclitaxel
50 mg/m2
45 mg/m2
160 mg/m2
2 Carboplatin
Paclitaxel
AUC 6 +
175 mg/m2
3 Paclitaxel 175 mg/m2
4 Carboplatin AUC 6
5 Doxorubicin 45 mg/m2
6 Cisplatin 50 mg/m2
7 Ifosfamide 1.6 g/m2
8 Vincristine 2 mg
AUC: area under the curve.
Table 3. Summary statistics for kinetic units values from the micro-
culture kinetic assay ranked by order of mean value of kinetic units
Drug Mean Standard
deviation
Minimum Maximum
Cisplatin+Doxorubicin
  +Paclitaxel
4.3 1.54 2.4 6.6
Carboplatin+Paclitaxel 3.4 1.60 1.3 5.4
Paclitaxel 3.1 1.73 0.7 6.0
Cisplatin 2.9 2.62 0.0 9.3
Ifosfamide 2.5 2.61 0.0 9.9
Doxorubicin 1.9 0.90 1.0 4.3
Carboplatin 1.8 1.89 0.0 5.1
Vincristine 1.0 1.20 0.0 3.5
Values are kinetic units.
to the Vmax of a control culture without drug. For convenience 
the Vmax is multiplied by 60 to convert the units from 
mOD/minute to mOD/hour. Finally, the data are normalized 
by multiplying with a standard cell density coefficient value 
(SCDC). The SCDC is calculated as follows: SCDC = 0.09/ 
(ODctrl−ODblank). The 0.09 was determined experimentally as 
the optimal OD difference between the initial OD given by the 
tumor cells and a blank well containing only the cell culture 
medium. The KU are therefore calculated with this formula:
KU: (Vmaxdrug-treated − Vmaxctrl) × 60 × 0.09/ (Mean ODctrl 
− Mean ODblank).
In initial evaluations, the chemosensitivity response was con-
sidered high when the value was above 4.0 KU, intermediate 
between 1.0-4.0 NKU, and not sensitive when below 1.0 KU.
MiCK KU data for different drugs and different doses was log-
ged into Microsoft Excel. Data were imported into SAS/ JMP 
for analysis.10 Concentrations lower than the clinical dose were 
routinely used in the assay as an internal control where less 
apoptosis would be induced by lower concentrations. The highest 
value of apoptosis was given by one of the two highest concen-
trations that were closest to the clinical doses. SAS/JMP was 
used to calculate summary statistics and perform statistical 
analysis. Subtracting one drug’s KU value from another drug’s 
KU value on a matched sample basis made comparisons be-
tween drugs. The nonparametric Wilcoxon test was then used 
to test for a statistical difference.11
RESULTS
Tumors of 19 patients were evaluated, and successful analy-
ses were obtained in 15 (78.9%). Patient characteristics are 
noted in Table 1. Table 2 summarizes the drug doses simu-
lated in the assay. 
The highest mean chemosensitivity of 4.3 KU was noted in 
the triple combination of cisplatin+doxorubicin+paclitaxel 
with a slightly lower mean chemosensitivity of 3.4 KU for car-
boplatin+paclitaxel (Table 3). Summary statistics indicated 
overall excellent activity of the three drug combination and in-
termediate activity for the two drug combination and each sin-
gle agent except vincristine.
In Table 4 is listed the absolute difference the mean MiCK re-
sponse from the drug combination to the mean response of 
constituent drugs. Doxorubicin was inferior and the differ-
ence was statistically significant from cisplatin+doxorubicin+ 
paclitaxel (p=0.02), and carboplatin was inferior and statisti-
cally different from carboplatin+paclitaxel (p=0.02). The 
other differences were not statistically significant (p＞0.05).
Eight patients had MiCK KU values recorded for at least one 
combination regiment (cisplatin+doxorubicin+paclitaxel or 
carboplatin+paclitaxel) and simultaneously at least one sin-
gle drug (paclitaxel, cisplatin, ifosfamide, doxorubicin, carbo-
platin, and vincristine). Of these eight patients, two (25%) 
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Table 4. Comparison of combination drug treatment versus single drug treatment of endometrial cancer
Comparison Mean absolute difference Larger mean p-value
Cisplatin+Doxorubicin+Paclitaxel vs. Doxorubicin 2.11 Cisplatin+Doxorubicin+Paclitaxel 0.02
Carboplatin+Paclitaxel vs. Carboplatin 1.40 Carboplatin+Paclitaxel 0.02
Table 5. The mean kinetic units of the microculture kinetic assay 
highly correlates (0.89) with the overall response rates of the GOG 
clinical trials13-19
Drug Mean, KU
GOG
response rate
Cisplatin+Doxorubicin
  +Paclitaxel
4.3 0.56
Paclitaxel 3.1 0.35
Cisplatin 2.9 0.2
Ifosfamide 2.5 0.26
Doxorubicin 1.9 0.25
Vincristine 1 0.18
GOG: Gynecologic Oncology Group, KU: kinetic units.
had the single drug MiCK KU value larger than the combina-
tion MiCK KU value. Specifically, as noted in Table 3, 
Ifosfamide (KU maximum of 9.9) and cisplatin (KU max-
imum of 9.3) were higher than the maximum KU of 6.6 for the 
combination of cisplatin+doxorubicin+paclitaxel. A 95% 
confidence interval for this proportion is 3.2% to 65.1%.12
The MiCK assay results were compared to clinical response 
rates in previously completed GOG trials as shown in Table 5. 13-19 
There was a high correlation between the demonstrated activ-
ity of chemotherapy drugs in vivo in multi-institutional trials 
and the chemosensitivity of patients’ cancer cells in the MiCK 
assay (Pearson’s correlation of 0.85, p＜0.0328).
DISCUSSION
The purpose of this study was to determine if the in vitro 
MiCK assay was feasible for use with endometrial cancer tis-
sue and if chemotherapy sensitivity would be consistent with 
previous GOG clinical results. Nineteen patients were in-
cluded in this study with four patients having no viable tumor 
cells for testing. The remaining 15 specimens were capable of 
being tested using the MiCK assay. A 78.9% (15/19) viable tu-
mor rate using overnight shipments and a remote central lab-
oratory is considered quite satisfactory and feasible for rou-
tine testing. The success rate for the MiCK assay is totally de-
pendent upon the collection of sufficient viable tumor that has 
been properly processed and transported to the lab where 
minimal numbers of tumor cells are available for testing.
Using the above panel of agents simulating clinical dose regi-
mens, the novel MiCK assay was successfully employed as an 
in vitro chemosensitivity test for endometrial cancer response. 
The chemosensitivity results of MiCK were compatible with 
GOG clinical trial findings.13-19
GOG trials indicate most patients are best treated with com-
bination chemotherapy. In this study, although based on wide 
confidence intervals because of the small number of samples, 
the results indicate that 25% of patients might be treated with 
single agent chemotherapy selected by the MiCK assay. 
Ifosfamide, cisplatin, paclitaxel appeared to have high activity 
as single agents. The MiCK assay may allow oncologists to 
identify patients for whom to consider single agent therapy.
In Table 3 is listed the relative efficacy of chemotherapy regi-
mens as determined by GOG clinical trials and confirmed by 
the MiCK assay. This trial indicates that this should be the or-
der of drug testing in future MiCK assay testing of endo-
metrial cancer specimens.
Receiver operator curves (ROC) were unable to be produced 
due to the small number of patients and outcome data from 
this feasibility study. A follow-up study for recurrent endo-
metrial cancer is in progress to correlate the MiCK assay with 
endometrial cancer chemotherapy response in a larger num-
ber of patients. Once enough data is collected, a model can be 
constructed to predict the probability of complete remission 
(CR) as a function of KU. DiaTech has a new master protocol 
in which all tumor types are eligible. Physicians may use the 
MiCK assay results, if they wish, and will report the drugs ac-
tually used, the patient response, time to progression, and 
survival. MiCK assay results will be correlated with choice of 
drugs (to determine how the physicians have used the assay 
results), response, time to progression, and survival.
From the study samples analyzed, the data demonstrate fea-
sibility in a clinical setting and suggest a potential valid way to 
test for chemosensitivity of endometrial cancer specimens.  
This data is also supported by results from breast cancer 
studies. In breast cancer, chemosensitivity to single and com-
bination drugs was successfully measured with the MiCK as-
say and apoptosis was decreased after prior chemotherapy.20 
The MiCK assay is a chemosensitivity assay that does not re-
quire cell proliferation. It counts the number of killed tumor 
cells and measures apoptosis directly, therefore results are 
generated within 72 hours. Chemoresistant assays are de-
pendent upon cell culture growth and measures apoptosis in-
directly by counting live tumor cells. In turn, chemoresistant 
assays can generally take 3 to 6 weeks to obtain results. The 
MiCK assay is unique since it determines drugs that work 
against tumor cells, and, on the contrary, chemoresistant as-
says determine chemotherapy drugs that do not work against 
tumor cells. The MiCK assay is a kinetic assay and reports 
measurements of apoptosis every 5 minutes, whereas the re-
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sistant assays measure once at completion of the test. 
The MiCK assay provides a possibility for initially selecting 
the best chemotherapy agent to treat many different cancers.  
Furthermore, this could allow for improving treatment out-
comes, decreasing adverse effects of chemotherapy, increas-
ing the patient’s quality of life, and reducing the cost of 
treatment.21,22 The MiCK assay may also be useful both for fu-
ture new drug testing and tailoring chemotherapy to an in-
dividual patient’s drug sensitivity profile.
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